Skip to main content
. Author manuscript; available in PMC: 2022 Jul 10.
Published in final edited form as: Oncogene. 2022 Jan 10;41(7):971–982. doi: 10.1038/s41388-021-02132-6

Figure 6. Gemcitabine and anti-CD73 combination therapy diminish tumor burden and improves survival.

Figure 6.

A-C Overall survival (A), tumor volume (B), and representative IHC images of tumor sections (C) from C57BL/6J mice orthotopically implanted with KPC1245 cells and treated with saline control, gemcitabine, anti-CD73 antibody, or the combination of gemcitabine and anti-CD73 antibody. Survival analysis was examined with Mantel-Cox log-rank comparison. Statistical significance for tumor growth was calculated by using a generalized linear mixed model for longitudinal log-normal data incorporating compound symmetry correlation among longitudinal data from the same subjects. Error bars depict the standard error of the mean. ***P < 0.001.